Subscribe To
89bio announces upsized pricing of $275 million common stock public offering
89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shar...
March 25, 2023, 10:11 am
Why shares of 89bio soared this week
89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH dru...
March 24, 2023, 10:57 am
89bio's public stock offering upsized by 38%, priced at a 4% discount
89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical com...
March 24, 2023, 7:21 am
89bio (etnb) up 25% on upbeat data from mid-stage nash study
Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis ...
March 23, 2023, 3:14 pm
Biotech stock surges on mid-stage drug trial success
The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biot...
March 22, 2023, 10:49 am
Why is 89bio (etnb) stock up 34% today?
89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b...
March 22, 2023, 9:30 am
89bio rockets 30% — and akero dives — on a scorching battle in liver disease
Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well...
March 22, 2023, 9:14 am
89bio: a promising nash innovator
As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer a...
March 17, 2023, 6:18 pm
Wall street analysts see an 80% upside in 89bio (etnb): can the stock really move this high?
The mean of analysts' price targets for 89bio (ETNB) points to an 80% upside in the stock. While this h...
March 15, 2023, 11:28 am
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
4 best breakout stocks to buy for superb returns
Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89bio (ETNB) have been selected as the...
February 24, 2023, 9:02 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharma...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharma...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharma...
February 21, 2023, 8:00 am
Orbimed advisors reduces position in 89bio
Fintel reports that Orbimed Advisors Llc has filed a 13D/A form with the SEC disclosing ownership of 1.50MM shares of ...
January 27, 2023, 10:27 pm
89bio (etnb) upgraded to strong buy: what does it mean for the stock?
89bio (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by ...
January 17, 2023, 1:33 pm